ASCO 2023 | BI 764532: a novel T-cell engager for patients with DLL3+ SCLC and NEC

Martin Wermke, MD, University Hospital Carl Gustav Carus, Dresden, Germany, describes the trial design of a Phase I trial (NCT04429087) of BI 764532, a DLL3/CD3 IgG-like T-cell engager, in patients with DLL3-positive small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC). The Phase I dose escalation trial will initially have a triweekly dosing schedule, followed by a weekly dosing schedule. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.